Prostate Cancer Clinical Trial 20213095

[LCID Study Number: 20213095]

DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801): A Randomised Phase 3 Double-blind, Placebocontrolled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localised Prostate Cancer

The purpose of this study is to determine the effectiveness of darolutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone analogue (LHRHA) in men having radiation therapy for localised prostate cancer at very high risk of recurrence.

Disease/Condition: Prostate Cancer

Department: Hematology and Oncology

Location(s): Lahey Hospital & Medical Center (Burlington); Lahey Medical Center, Peabody

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3421

View NCT ID 04136353 on ClinicalTrials.gov
Protocol #: 20213095
Principal Investigator(s): Brendan J. Connell
Study Coordinator(s): Thea Miller
Trial Phase: Sponsor Initiated Study Phase 3